NOVO
Novatti Group Limited
🇦🇺 ASX
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
0
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Novatti Group Limited - Option Expiring 31-Jan-2027
📈 Performance
Price History
N/A
1M
All Time
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$0.01
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in NOVO
0
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in NOVO
N/A
NOVO investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
🙋 Legal gender of investors
Female
Male
Pearlers who invest in NOVO also invest in...
Want more shares? Try these...
Noxopharm Ltd. engages in the research and development of drugs. The company is headquartered in Castle Hill, New South Wales and currently employs 1,000 full-time employees. The company went IPO on 2016-08-09. The company is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. The company utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.
🙌 Performance (5Yr p.a)
-13.30%
📊 Share price
$0.10 AUD
🧬 BIOTECHNOLOGY
Novatti Group Ltd. provides software technology and systems integration services. The company is headquartered in Melbourne, Victoria. The company went IPO on 2016-01-18. The Company’s segments include Technology, Business automation, Acquiring, Alternative payments, Banking services, Issuing, and ATX payments. Technology segment develops, deploys, and supports specialized mobile and alternate payment technology, primarily through the deployment of the Novatti Wallet Platform. Business automation segment automates business processes, including customer engagement, subscription management and embedded payments. Acquiring segment accepts a range of payments. Alternative payments segment includes bill payments for international and local university and college students. Banking services segment offers customers an alternative payment method in the form of a prepaid cash voucher. Issuing segment provides a payment system centered around digital and physical prepaid, gift and debit cards for a variety of fintechs and commercial enterprises. ATX payments segment provides a payments network across Malaysia.
🙌 Performance (5Yr p.a)
-17.02%
📊 Share price
$0.03 AUD
🤖 TECHNOLOGY
